Reata to re-file bardoxolone with FDA following positive Ph III data

12 November 2019
reata_large

US biotech Reata Pharmaceuticals (Nasdaq: RETA) says it will seek Food and Drug Administration approval for what would be the first drug to reverse kidney damage and prevent the need for dialysis or transplant.

Reata’s data are in patients with a rare genetic form of chronic kidney disease (CKD) known as Alport syndrome (AS). Notwithstanding what seems to be a positive development, Reata’s shares fell 7.8% to $197.00 in post-market trading on Monday.

New data from a registrational Phase III study shows drug candidate, bardoxolone (bard), met its primary endpoint of improving estimated glomerular filtration rate (eGFR), a measure of kidney function. Patients had a 9.5 ml/min improvement in eGFR compared to placebo after 48 weeks of daily bard treatment. Even when patients were removed from drug for four weeks, eGFR was still improved 5.14 ml/min, indicating that bard is having a true disease modifying effect.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology